News and Events

Cancer Breakthroughs 2020: The Nation’s First Neoepitope Antibody Immunotherapy Phase II Trial Demonstrating Safety and Prolonged Survival in Patients with Metastatic End-Stage Colon Cancer October 31, 2016

Embed from Getty Images Clinical investigators from Moffitt and Walter Reed Army Institute present data of first Phase II Neoepitope Antibody Immunotherapy Clinical Trial completed at John’s Hopkins, Duke and Moffitt as a potential new immunotherapy treatment for...

Cancer Breakthroughs 2020 Reaches First Clinical Trial Milestone: Immunotherapy Trial Demonstrates Encouraging Survival Rates in Patients with Metastatic Colorectal Cancer‎ Who Failed all Standard Therapy

Over 30% of patients who failed all standard chemo and antibody therapy remain alive after neo-epitope immunotherapy Ensituximab, with the longest current survivor more than two years after treatment Results of this promising clinical trial to be presented at the ASCO...

Precision Biologics

info@precision-biologics.com
214-696-4999
5910 North Central Expressway, Suite 1300 Dallas, TX 75206